Tissue Inhibitor of Metalloproteinase-1 is an Early Marker of Acute Endothelial Dysfunction in a Rodent Model of Venous Oxidative Injury

Annals of Vascular Surgery

Volumn 23, Issue 4, 2009, Pages 498-505

  Moore, Rashida ^a,b   Hawley, Angela ^a   Sigler, Robert ^c   Farris, Diana ^a   Wrobleski, Shirley ^a   Ramacciotti, Eduardo ^a   Myers, Daniel ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Vet Pathology and IND Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; ROSE BENGAL; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CLINICAL EVALUATION; CONTROL GROUP; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RAT; GENE EXPRESSION; ILLUMINATION; MALE; MORPHOMETRICS; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; VEIN INJURY; VEIN WALL;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; MALE; NEUTROPHIL INFILTRATION; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; ROSE BENGAL; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION; VASCULAR DISEASES; VENA CAVA, INFERIOR;

EID: 67349104387     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2009.03.005     Document Type: Article

References (46)

1. Szasz T., Thakali K., Fink G.D., et al. A comparison of arteries and veins in oxidative stress: producers, destroyers, function, and disease. Exp Biol Med (Maywood) 232 (2007) 27-37
2. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 (2000) 840-844
3. Gimbrone Jr. M.A. Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 75 (1995) 67B-70B
4. Altman R. Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. Thromb J 1 (2003) 4
5. Laursen J.B., Somers M., Kurz S., et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103 (2001) 1282-1288
6. Bonetti P.O., Lerman L.O., and Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23 (2003) 168-175
7. Moreno P.R., Bernardi V.H., Lopez-Cuellar J., et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 94 (1996) 3090-3097
8. Massova I., Kotra L.P., Fridman R., et al. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12 (1998) 1075-1095
9. Jian Liu K., and Rosenberg G.A. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 39 (2005) 71-80
10. Allaire E., Forough R., Clowes M., et al. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 102 (1998) 1413-1420
11. Mecham R.P., Broekelmann T.J., Fliszar C.J., et al. Elastin degradation by matrix metalloproteinases. Cleavage site specificity and mechanisms of elastolysis. J Biol Chem. 272 (1997) 18071-18076
12. Murphy G., Cockett M.I., Ward R.V., et al. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 277 (1991) 277-279
13. Badier-Commander C., Verbeuren T., Lebard C., et al. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol 192 (2000) 105-112
14. Dollery C.M., McEwan J.R., and Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res 77 (1995) 863-868
15. Gomez D.E., Alonso D.F., Yoshiji H., et al. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
16. Puhakka H.L., Turunen P., Rutanen J., et al. Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model. J Vasc Res 42 (2005) 361-367
17. Eitzman D.T., Westrick R.J., Xu Z., et al. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 20 (2000) 1831-1834
18. Souba W.W., and Wilmore D.W. Surgical Research (2001), Academic Press, San Diego
19. Chao D.T., and Korsmeyer S.J. BCL-2 family: regulators of cell death. Annu Rev Immunol 16 (1998) 395-419
20. Kowaltowski A.J., and Fiskum G. Redox mechanisms of cytoprotection by Bcl-2. Antioxid Redox Signal 7 (2005) 508-514
21. Eitzman D.T., Westrick R.J., Xu Z., et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96 (2000) 4212-4215
22. Kim Y., Nakase H., Nagata K., et al. Observation of arterial and venous thrombus formation by scanning and transmission electron microscopy. Acta Neurochir (Wien) 146 (2004) 45-51
23. Przyklenk K., and Whittaker P. Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals. Lasers Med Sci 22 (2007) 42-45
24. Rosen E.D., Raymond S., Zollman A., et al. Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. Am J Pathol 158 (2001) 1613-1622
25. Saniabadi A.R., Umemura K., Matsumoto N., et al. Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb Haemost 73 (1995) 868-872
26. Silva V.M., Corson N., Elder A., et al. The rat ear vein model for investigating in vivo thrombogenicity of ultrafine particles (UFP). Toxicol Sci 85 (2005) 983-989
27. Tayebjee M.H., Lip G.Y., Blann A.D., et al. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 115 (2005) 205-210
28. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
29. Brew K., Dinakarpandian D., and Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477 (2000) 267-283
30. Fassina G., Ferrari N., Brigati C., et al. Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis 18 (2000) 111-120
31. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
32. Garbin U., Fratta Pasini A., Stranieri C., et al. Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells. Mediators Inflamm 2008 (2008) 367590
33. Griendling K.K., Sorescu D., Lassegue B., et al. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb. Vasc. Biol. 20 (2000) 2175-2183
34. Kunsch C., and Medford R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 85 (1999) 753-766
35. Lijnen HR. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb. 2003/2004;33:275-281.
36. Lijnen H.R., Soloway P., and Collen D. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. Circ Res 85 (1999) 1186-1191
37. Furman C., Luo Z., Walsh K., et al. Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery. FEBS Lett 531 (2002) 122-126
38. Turunen M.P., Puhakka H.L., Koponen J.K., et al. Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther 6 (2002) 306-312
39. Kadl A., and Leitinger N. The role of endothelial cells in the resolution of acute inflammation. Antioxid Redox Signal 7 (2005) 1744-1754
40. Myers Jr. D., Farris D., Hawley A., et al. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J Surg Res 108 (2002) 212-221
41. Myers D.D., Hawley A.E., Farris D.M., et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 38 (2003) 1075-1089
42. Myers Jr. D.D., Henke P.K., Bedard P.W., et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg 44 (2006) 625-632
43. Myers Jr. D.D., Rectenwald J.E., Bedard P.W., et al. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg 42 (2005) 329-336
44. Tesfamariam B., and DeFelice A.F. Endothelial injury in the initiation and progression of vascular disorders. Vascul Pharmacol 46 (2007) 229-237
45. Bannerman D.D., Sathyamoorthy M., and Goldblum S.E. Bacterial lipopolysaccharide disrupts endothelial monolayer integrity and survival signaling events through caspase cleavage of adherens junction proteins. J Biol Chem 273 (1998) 35371-35380
46. Stefanec T. Endothelial apoptosis: could it have a role in the pathogenesis and treatment of disease?. Chest 117 (2000) 841-854